CytoSorbents Corp (CTSO): יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

The EV/EBITDA market price visualization for Cytosorbents (CTSO) is 0.00. Cytosorbents leads the blood filtration segment by creating unique columns to combat sepsis and toxins. Global demand for extracorporeal therapy is steadily growing due to the expansion of intensive care unit networks. The business relies on regular sales of high-margin replacement cartridges, which ensure a constant cash flow from the installed equipment base.

Steady demand for blood purification systems in intensive care units creates a reliable cash flow for Cytosorbents (CTSO), which is assessed via the EV/EBITDA multiple chart. This metric compares the total enterprise value, including debt, against operating profit, allowing investors to determine if the asset is overvalued or to identify an entry point when fundamental indicators are undervalued.